Vivani Medical (VANI) Financials

Vivani Medical (NASDAQ: VANI) remains a pre-revenue biotech story with no product sales yet, so the key investor question is not near-term profitability but whether the company can fund its pipeline long enough to reach meaningful clinical or strategic milestones.

Looking at the last four years of quarterly statements, the financial picture is consistent: heavy operating losses, recurring cash burn, and repeated equity issuance to stay funded. The good news is that Vivani ended Q1 2026 with a much stronger cash balance than it had a year ago. The trade-off is dilution: the company has repeatedly tapped shareholders for capital.

• Cash improved sharply in Q1 2026, with cash and equivalents rising to $19.7 million from $2.6 million at the end of Q3 2025 and from $13.0 million at the end of Q1 2025.
• Q1 2026 financing activity was substantial, including $9.8 million of common equity issuance, which helped drive the quarter’s $3.5 million net increase in cash.
• Operating expenses were slightly lower sequentially in Q1 2026, with total operating expenses of $6.8 million versus $6.8 million in Q4 2025 and $6.7 million in Q3 2025, showing some cost stability.
• R&D spending remained a major investment, suggesting the company is still actively pushing its pipeline rather than cutting back on development.
• Vivani continues to report no revenue, so the business is still entirely dependent on external funding and clinical progress.
• Q1 2026 operating cash burn remained high at $6.2 million, only modestly better than $6.7 million in Q4 2025 and $6.4 million in Q3 2025.
• Balance sheet leverage is limited in the traditional sense, but liabilities are still meaningful at $23.3 million versus $42.4 million in total assets.
• The company remains deeply unprofitable, posting a Q1 2026 net loss of $6.8 million, or $(0.08) per share.
• Share dilution is a persistent issue; weighted average basic shares rose to 81.3 million in Q1 2026 from 59.2 million in Q2 2025 and 52.2 million in Q1 2024.
• Retained earnings remain severely negative at $(155.3) million, underscoring the long history of cumulative losses.

Over the broader four-year period, Vivani’s quarterly losses have stayed in a fairly tight band, generally around $6 million to $7 million per quarter. That suggests the business model has not yet reached operating leverage. In fact, R&D and SG&A have remained elevated even as the company has expanded its capital base.

One encouraging trend is that the cash position is now much healthier than it was during the middle of 2025, when cash fell to $2.6 million in Q3 2025. That rebound likely reduces near-term liquidity pressure. Still, investors should view the current balance sheet as a temporary runway extension, not a sign of self-sustaining operations.

Bottom line: Vivani Medical has improved its liquidity, but it is still an early-stage, cash-burning biotech with no revenue and ongoing dilution risk. The stock likely remains highly sensitive to clinical updates, capital raises, and any signs that operating losses are beginning to narrow.